




The relative strengths and weaknesses of Ernexa Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Ernexa Therapeutics Inc compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 21% points. The greatest weakness of Ernexa Therapeutics Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 234% points.

The company's Economic Capital Ratio, given in the ranking table, is 148%, being 115% points below the market average of 263%.

Input Variable	Value in 1000 USD
Assets, Current	9,110
Cost of Goods Sold	0
Intangible Assets	988
Liabilities, Current	5,122
Liabilities, Non-Current	0
Other Assets	2,395
Other Compr. Net Income	-307
Other Expenses	13,366
Other Liabilities	7,438
Other Net Income	-319
Other Revenues	24,519
Property and Equipment	3,915
Research and Development	0
Selling, General and Administrative Expense	18,060

Output Variable	Value in 1000 USD
Assets	16,408
Liabilities	12,560
Expenses	31,426
Revenues	24,519
Stockholders Equity	3,848
Net Income	-7,226
Comprehensive Net Income	-7,380
BaseVar	42,770
ECR before Limited Liability	7.0%
Economic Capital Ratio	148%